Folgen
Keine Story von Norgine mehr verpassen.
Filtern
  • 09.04.2018 – 13:01

    NHS England to Fund Endocuff Vision® for Cancer Screening Colonoscopies Bowel

    Amsterdam (ots/PRNewswire) - Norgine B.V. today announced that its UK affiliate has received funding for ENDOCUFF VISION® through the NHS Innovation Technology Payment 2018/19 (ITP) scheme. The NHS ITP Programme aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake of innovative products or technologies and is a ...

  • 11.05.2017 – 13:16

    Merus Labs and Norgine Enter Into a Definitive Arrangement Agreement

    Toronto and Amsterdam (ots/PRNewswire) - - Norgine to acquire all outstanding shares of Merus for $1.65 per share in cash Merus Labs International Inc. ("Merus" or the "Company") TSX: MSL, NASDAQ: MSLI and Norgine B.V. ("Norgine") announced today that they have entered into a definitive agreement (the "Arrangement Agreement") under which Norgine will acquire all of the issued and outstanding common shares of Merus for ...

  • 24.05.2013 – 12:02

    PBAC Approves XIFAXAN® (Rifaxamin a) 550 mg Cost Effectiveness in Australia

    London (ots/PRNewswire) - Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy (HE) where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition ...

  • 18.12.2012 – 08:03

    Norgine and SpePharm Holding Enter Into Joint Venture

    Amsterdam (ots/PRNewswire) - Norgine BV (Amsterdam) and SpePharm Holding BV (Amsterdam) announced today that they have concluded a broad collaboration agreement under which the two companies have invested in a 50:50 joint venture, SpePharm AG, which has acquired the entire product portfolio of SpePharm Holding, including Savene(R), MuGard(R), Xerotin(R), PROther(R) and the Dantrium(R) brands. The new joint venture will ...